 BERWYN, Pa.--BUSINESS WIRE-- earnings--Virpax Pharmaceuticals, Inc. Virpax or the Company NASDAQ:VRPX, today announced its financial results for the quarter ended June 30, 2021, and other recent developments. We continue to advance our product candidate pipeline focused on pain, CNS and anti-viral indications. Two of our product candidates, EpoladermTM and ProbudurTM, will utilize an accelerated 505b2 pathway and are currently being funded through proceeds from our initial public offering wh 